NumFin

Homology Medicines, Inc.

符号: 0T6G.L

LSE

21.56

USD

今天的市场价格

  • -0.7390

    市盈率

  • -0.0083

    PEG比率

  • 283.62M

    MRK市值

  • 0.00%

    DIV收益率

Homology Medicines, Inc. (0T6G-L) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 Homology Medicines, Inc. (0T6G.L). 的默认数据。公司收入显示 NaN M 的平均值，即 NaN % 增长率。整个期间的平均毛利润为 NaN M，即 NaN %. 平均毛利率为 NaN %. 公司去年的净收入增长率为 NaN %，等于 NaN % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 Homology Medicines, Inc. 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为. 回顾过去一年，总资产变化为 NaN. 股东权益总额所体现的股东价值是以报告货币计算的 NaN. 这方面的年同比变化率为 NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

balance-sheet.row.cash-and-short-term-investments

082.7175155.9
217.4
262.4
214.7
129.7
11.4

balance-sheet.row.short-term-investments

043.414147.5
0
208.6
176.5
78.1
0

balance-sheet.row.net-receivables

0000
0.4
0.4
0.8
0
0

balance-sheet.row.inventory

0000
0
0
0
0
0

balance-sheet.row.other-current-assets

01.3636
1.7
3.8
6.1
1.9
0.6

balance-sheet.row.total-current-assets

083.9181191.9
219.6
266.6
221.7
131.6
12

balance-sheet.row.property-plant-equipment-net

00.721.617.9
42.9
42.7
35.6
3.2
2

balance-sheet.row.goodwill

0000
0
0
0
0
0

balance-sheet.row.intangible-assets

0000
0
0
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000
0
0
0
0
0

balance-sheet.row.long-term-investments

0025.82
1.3
1.3
0
0
0

balance-sheet.row.tax-assets

0221.600
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0000
0
0
-35.6
-3.2
-2

balance-sheet.row.total-non-current-assets

0222.247.519.8
44.2
44
35.6
3.2
2

balance-sheet.row.other-assets

0000
0
0
1.8
2.8
0.3

balance-sheet.row.total-assets

0306.1228.5211.7
263.7
310.6
259.1
137.5
14.2

balance-sheet.row.account-payables

03.21.12.4
4.7
2.6
15.7
2.5
0.9

balance-sheet.row.short-term-debt

01.31.60.2
2.5
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0

balance-sheet.row.long-term-debt-total

049.411.95
0
0
0
0
0

Deferred Revenue Non Current

0-104.401.2
32.1
30.1
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-

balance-sheet.row.other-current-liab

0718.711.4
9.8
9
6.8
6.3
1.2

balance-sheet.row.total-non-current-liabilities

0221.627.924.8
45.1
39.7
0
0
0

balance-sheet.row.other-liabilities

0000
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

06.827.923.7
12.9
0
0
0
0

balance-sheet.row.total-liab

0233.150.542.1
67.7
52.1
22.5
8.9
2.1

balance-sheet.row.preferred-stock

0111.4111.4111.4
0
0
0
137.8
21.6

balance-sheet.row.common-stock

0000
0
0
0
0
0

balance-sheet.row.retained-earnings

0-542.1-429.1-424.1
-328.4
-199.7
-95.8
-40.2
-10.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-0.40
0
0.2
0
0
0

balance-sheet.row.other-total-stockholders-equity

0503.6496.1482.3
524.4
458
292.1
0.7
0.3

balance-sheet.row.total-stockholders-equity

073178169.7
196
258.5
196.4
98.3
11.7

balance-sheet.row.total-liabilities-and-stockholders-equity

0306.1228.5211.7
263.7
310.6
0
0
0

balance-sheet.row.minority-interest

0000
0
0
0
0
0

balance-sheet.row.total-equity

073178169.7
196
258.5
196.4
98.3
11.7

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-

Total Investments

043.4166.949.4
1.3
209.9
176.5
78.1
0

balance-sheet.row.total-debt

01.329.523.9
15.4
0
0
0
0

balance-sheet.row.net-debt

0-37.9-4.5-84.4
-202
-53.8
-38.2
-51.6
-11.4

现金流量表

在 Homology Medicines, Inc. 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 NaN 的转变。该公司最近通过发行 NaN 扩大了股本，与上一年相比出现了NaN 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到NaN. 与上一年相比， NaN 发生了变化. 在同一时期，公司记录了 NaN, NaN 和 NaN，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为NaN，同比差异为NaN. 此外，公司还将NaN 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 NaN，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

cash-flows.row.net-income

0-113-5-95.8
-128.7
-103.9
-55.6
-30
-8

cash-flows.row.depreciation-and-amortization

00.62.69.5
8.9
6.3
1.3
0.7
0.2

cash-flows.row.deferred-income-tax

00-19.2-38.8
-28.6
-24.7
0
0
0

cash-flows.row.stock-based-compensation

0013.117.2
13.2
7.6
2.6
0.3
0.2

cash-flows.row.change-in-working-capital

0-7.23.4-41.8
11.5
0.5
0
0
0

cash-flows.row.account-receivables

0000
0
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0

cash-flows.row.account-payables

02.1-1-2.5
2.5
-4.5
0
0
0

cash-flows.row.other-working-capital

0-9.34.3-39.3
9.1
4.9
0
0
0

cash-flows.row.other-non-cash-items

023.4-108.439.8
29.3
22.9
9.1
35.5
-0.8

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-0.2-1.3-2.4
-3.7
-21.8
-24.9
-2
-2

cash-flows.row.acquisitions-net

00.613048.4
-208.6
30
0
0
0

cash-flows.row.purchases-of-investments

0-73.2-157.5-97.4
-20
-286.4
0
0
0

cash-flows.row.sales-maturities-of-investments

0174.265.549
228.6
256.4
0
0
0

cash-flows.row.other-investing-activites

000-48.4
208.6
-30
-96.8
-79.6
-0.3

cash-flows.row.net-cash-used-for-investing-activites

0101.336.7-50.8
204.9
-51.8
-121.8
-81.5
-2.3

cash-flows.row.debt-repayment

0000
0
0
0
0
0

cash-flows.row.common-stock-issued

00.20.652.2
53.1
158.2
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0

cash-flows.row.dividends-paid

0000
0
0
0
0
0

cash-flows.row.other-financing-activites

000.652.2
53.1
158.2
151
115.2
0.4

cash-flows.row.net-cash-used-provided-by-financing-activities

00.20.652.2
53.1
158.2
151
115.2
0.4

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
1.8
0
21.8

cash-flows.row.net-change-in-cash

05.3-74.4-109
163.7
15.6
-11.6
40.2
11.4

cash-flows.row.cash-at-end-of-period

039.334108.4
217.4
53.8
40
51.6
11.4

cash-flows.row.cash-at-beginning-of-period

034108.4217.4
53.8
38.2
51.6
11.4
0

cash-flows.row.operating-cash-flow

0-96.2-113.7-109.8
-94.3
-91.4
-42.6
6.5
-8.5

cash-flows.row.capital-expenditure

0-0.2-1.3-2.4
-3.7
-21.8
-24.9
-2
-2

cash-flows.row.free-cash-flow

0-96.5-114.9-112.1
-98.1
-113.2
-67.5
4.5
-10.5

利润表行

Homology Medicines, Inc. 的收入与上期相比变化了 NaN%。据报告, 0T6G.L 的毛利润为 NaN。该公司的营业费用为 NaN，与上年相比变化了 NaN%. 折旧和摊销费用为 NaN，与上一会计期间相比变化了 NaN%. 营业费用报告为 NaN，显示NaN% 的同比变化。 销售和营销费用为 NaN, 其中 NaN% 与上年相比发生了变化。 基于近期数据的EBITDA为 NaN，同比增长NaN%. 营业收入为 NaN，与上年相比变化了NaN%. 净利润的变化率为 NaN%。去年的净收入为NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016

income-statement-row.row.total-revenue

01.23.234
2.7
1.7
5.3
0
0

income-statement-row.row.cost-of-revenue

00.62.69.5
100.4
89.4
47.9
21.4
0

income-statement-row.row.gross-profit

00.60.624.4
-97.7
-87.7
-42.6
-21.4
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0

income-statement-row.row.operating-expenses

092.7133.9120.4
124.1
105.3
17.3
9.2
8.1

income-statement-row.row.cost-and-expenses

093.3136.5129.9
133
111.6
65.2
30.5
8.1

income-statement-row.row.interest-income

05.63.20.2
1.6
6
4.3
0.5
0

income-statement-row.row.interest-expense

0000
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

05134.50.2
1.6
6
4.3
-0.3
2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0

income-statement-row.row.total-operating-expenses

05134.50.2
1.6
6
4.3
-0.3
2

income-statement-row.row.interest-expense

0000
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

00.62.69.5
8.9
6.3
1.3
0.7
0.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-

income-statement-row.row.operating-income

0-92.1-133.3-95.9
-130.3
-109.9
-59.9
-29.7
-10

income-statement-row.row.income-before-tax

0-87.11.2-95.8
-128.7
-103.9
-55.6
-30
-8

income-statement-row.row.income-tax-expense

00.30.70.5
0
0
0
0
0

income-statement-row.row.net-income

0-113-5-95.8
-128.7
-103.9
-55.6
-30
-8
类似股票
您可能还对以下内容感兴趣：
0HL9.L
Affimed N.V..
5.31 USD
LSE
0J2O.L
Halozyme Therapeutics, Inc..
43.365 USD
LSE
W8A.DE
Walgreens Boots Alliance Inc.
15.964 EUR
XETRA
0UNL.L
Nektar Therapeutics.
1.65 USD
LSE
0OCQ.L
Transgene SA.
1.248 EUR
LSE
0RD1.L
Camurus AB (publ).
504.2706 SEK
LSE
0QKQ.L
Relief Therapeutics Holding AG.
1.2 CHF
LSE
0HOJ.L
Blueprint Medicines Corporation.
91.075 USD
LSE
0574.HK
Pa Shun International Holdings Limited.
0.05 HKD
HKSE
0JDB.L
Invitae Corporation.
0.0035 USD
LSE

常见问题

什么是 Homology Medicines, Inc. (0T6G.L) 总资产是多少？

Homology Medicines, Inc. (0T6G.L) 总资产为 306119000.000.

什么是企业年收入？

年收入为 N/A.

企业利润率是多少？

公司利润率为 2.827.

什么是公司自由现金流？

自由现金流为 -22.864.

什么是企业净利润率？

净利润率为 8.364.

企业总收入是多少？

总收入为 6.819.

什么是 Homology Medicines, Inc. (0T6G.L) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 -112961000.000.

公司总债务是多少？

债务总额为 1318000.000.

营业费用是多少？

运营支出为 92680000.000.

公司现金是多少？

企业现金为 0.000.